MRI Based Biomarkers in Pediatric Autoimmune Liver Disease

Description

Autoimmune liver diseases (AILD), which include Primary Sclerosing Cholangitis (PSC) and Autoimmune Hepatitis (AIH) are a common etiological factors for chronic liver disease among adolescents. In all these conditions, autoimmune lymphocyte responses are thought to orchestrate inflammatory injury against hepatocytes (primarily in AIH) or cholangiocytes (in PSC). In this proposal we aim to evaluate the Magnetic Resonance Imaging (MRI) modalities; MR cholangiopancreatography (MRCP) and MR elastography (MREL), as non-invasive biomarkers to assess two primary pathophysiological processes of AILD: bile duct damage and liver fibrosis. In this cross-sectional study MRI based findings of bile duct injury and liver fibrosis will be correlated with both liver histology and circulating biomarkers of these disease processes.

Conditions

Autoimmune Liver Disease, Primary Sclerosing Cholangitis, Autoimmune Hepatitis

Talk to us

Study Overview

On this page

Study Details

Study overview

Autoimmune liver diseases (AILD), which include Primary Sclerosing Cholangitis (PSC) and Autoimmune Hepatitis (AIH) are a common etiological factors for chronic liver disease among adolescents. In all these conditions, autoimmune lymphocyte responses are thought to orchestrate inflammatory injury against hepatocytes (primarily in AIH) or cholangiocytes (in PSC). In this proposal we aim to evaluate the Magnetic Resonance Imaging (MRI) modalities; MR cholangiopancreatography (MRCP) and MR elastography (MREL), as non-invasive biomarkers to assess two primary pathophysiological processes of AILD: bile duct damage and liver fibrosis. In this cross-sectional study MRI based findings of bile duct injury and liver fibrosis will be correlated with both liver histology and circulating biomarkers of these disease processes.

Cross-sectional Study for Assessment of MRI Based Biomarkers of Bile Duct Injury and Hepatic Fibrosis in Pediatric Onset Autoimmune Liver Disease

MRI Based Biomarkers in Pediatric Autoimmune Liver Disease

Condition
Autoimmune Liver Disease
Intervention / Treatment

-

Contacts and Locations

Cincinnati

Cincinnati Childrens Hospital Medical Center, Cincinnati, Ohio, United States, 45229

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Age 6-23 years old.
  • 2. Established or suspected clinical diagnosis of AIH or PSC.
  • 1. History of liver transplantation.
  • 2. Chronic Hepatitis B or untreated hepatitis C virus infection.
  • 3. Pregnancy.
  • 4. Absolute contraindication for MRI (e.g. pacemaker, metallic implants, claustrophobia).
  • 5. Diagnosis of cystic fibrosis or biliary atresia
  • 6. Diagnosis of cardiac hepatopathy.
  • 7. Diagnosis of Wilson's disease, Alpha-1 Antitrypsin deficiency, or Glycogen storage disease.
  • 8. Skin conditions which could be aggravated by MREL (i.e. Epidermolysis bullosa).

Ages Eligible for Study

6 Years to 23 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Children's Hospital Medical Center, Cincinnati,

Alexander Miethke, MD, PRINCIPAL_INVESTIGATOR, Cincinnati Childrens Hospital Medical Center

Study Record Dates

2027-01-30